NCT04328129 (EPI-COVID-19) is a NA clinical trial of Human biological samples in Coronavirus Infections, sponsored by Institut Pasteur.

Who is sponsoring NCT04328129?

NCT04328129 is sponsored by Institut Pasteur.

What drugs are being tested in NCT04328129?

Interventions in NCT04328129: Human biological samples.

What condition does NCT04328129 study?

NCT04328129 studies Coronavirus Infections, Severe Acute Respiratory Syndrome, SARS-CoV Infection.

Is NCT04328129 still recruiting?

NCT04328129 is currently completed. Last updated 15 February 2022.

Last reviewed 2022-02-15 · How we verify

NCT04328129: EPI-COVID-19

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Household Transmission Investigation Study for COVID-19 in Tropical Regions

Completed NA Last updated 15 February 2022

What this trial tests

NA trial testing Human biological samples in Coronavirus Infections in 245 participants. Completed in 30 September 2021.

Timeline

23 March 2020

Primary endpoint
30 September 2021

30 September 2021

Quick facts

Lead sponsor	Institut Pasteur
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	screening
Enrollment	245
Start date	23 March 2020
Primary completion	30 September 2021
Estimated completion	30 September 2021
Sites	4 locations across French Guiana, Guadeloupe, New Caledonia

Drugs / interventions tested

Human biological samples

Conditions studied

Coronavirus Infections — all drugs for Coronavirus Infections →
Severe Acute Respiratory Syndrome — all drugs for Severe Acute Respiratory Syndrome →
SARS-CoV Infection — all drugs for SARS-CoV Infection →

Sponsor

Institut Pasteur — full company profile →

Who can join

Eligibility, any sex, with Coronavirus Infections or Severe Acute Respiratory Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a interventional study that present minimal risks and constraints to evaluate the presence of novel coronavirus (SARS-CoV-2) or antibodies among individuals living in households where there is a confirmed coronavirus case in order to provide useful information on the proportion of symptomatic forms and the extent of the virus transmission in tropical regions such as French Guiana, Guadeloupe and New-Caledonia.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Current updates on the European and WHO registered clinical trials of coronavirus disease 2019 (COVID-19).
Verma HK, Merchant N, Verma MK, Kuru Cİ, et al · · 2020 · cited 21× · PMID 32792167 · DOI 10.1016/j.bj.2020.07.008
Comparison of COVID-19 studies registered in the clinical trial platforms: A research ethics analysis perspective.
Buruk B, Guner MD, Ekmekci PE, Celebi AS. · · 2022 · cited 4× · PMID 34515393 · DOI 10.1111/dewb.12333

Verify or expand the search:

Other trials of Human biological samples

Trials testing the same drug.

NCT04644159 — Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation, in Early 2020 [COVID-19 · completed
NCT03829735 — Neonatal Vaccination Against Hepatitis B in Africa - Sero-survey in Senegal · NA · withdrawn
NCT03357536 — Genetic Susceptibility to Listeriosis · NA · recruiting
NCT03219827 — Pilot Study: Characterization of the Immune Phenotype of Patients Allergic to Wasp Venom or Penicillin · NA · completed
NCT02789995 — Dysfunctions of Human Muscle Stem Cells in Sepsis · NA · completed

Other recruiting trials for Coronavirus Infections

Currently open trials in the same condition.

NCT06631287 — Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Sym · Phase 3 · recruiting
NCT05276388 — Establishment of a Biological Biobank of Subjects Vaccinated Against SARS-CoV-2 Infection (COVID-19) · active not recruiting
NCT04429594 — Study of the Incidence of SARS-CoV-2 Infection (COVID-19) · NA · recruiting
NCT04327570 — In-depth Immunological Investigation of COVID-19. · recruiting
NCT04318366 — COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor · recruiting

Other Institut Pasteur trials

Trials by the same sponsor.

NCT07205913 — Gut Microbiota, Diet-INDuced Obesity and Type 2 Diabetes in New Caledonia - MIND · not yet recruiting
NCT06945822 — Characterizing the Host Response to Leptospirosis for Better Diagnosis and Prognosis - NIHFI · NA · not yet recruiting
NCT05821478 — Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients · Phase 3 · recruiting
NCT06769815 — Host Immunity, Plasmodium and Pathogens Co-Infections · NA · not yet recruiting
NCT06718127 — Description of the Immune Response to Yellow Fever Vaccination · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04328129 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Pasteur
Last refreshed: 15 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04328129.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing